Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

PSMD3 orchestrates metabolic reprogramming and immunogenic cell death in multiple myeloma

View Full Paper
Ask AI
Bookmark
Share

Authors

MHMu HaoYSYan SongKAKenneth C. Anderson

Discussion

Loading...

Member takes

Overview

Observational analysis reveals that targeting PSMD3 reduces immune suppression and induces immunogenic cell death in multiple myeloma cells.

Key Points

  • Targeting PSMD3 was shown to overcome resistance to proteasome inhibitors in multiple myeloma.
  • In vivo experiments demonstrated a significant suppression of tumor growth and activation of anti-tumor immune responses.
  • Assessment using preclinical models provided a clear link between PSMD3 depletion and mitochondrial dysfunction.
  • These findings underscore the necessity of developing PSMD3-targeted therapies to enhance immune-mediated clearance of multiple myeloma.

Cite This Study

Hao et al. (2025) studied this question.

synapsesocial.com/papers/69362f714fa91c937236e207https://doi.org/10.1182/blood-2025-3926
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Multi-omics analysis identifies neutrophil degranulation as a PSMD3-regulated pathway in FLT3-mutated AML2025
  2. 2DDX3X facilitates adaption to proteotoxic stress by regulating the translation of MAPKAPK2 and the stability of TMCO1 via stress granules in multiple myeloma2025
  3. 3Synthetic lethal targeting of PSMC2-dependent p97-adapted proteasome complexes that confer chemoresistance in multiple myeloma2025 · 1 citations
  4. 4Immunomodulatory drugs rewire mTORC1-dependent pathways in multiple myeloma to trigger cytotoxicity and immunogenic cell death2025
  5. 5Multi-omics profiling reveals an immunosuppressive microenvironment and PRL-3 as a therapeutic target in myeloma extramedullary disease2025